{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:18:57Z","timestamp":1792793937411,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1564,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Chipscreen Biosciences, Ltd","id":[{"id":"https:\/\/ror.org\/04b1hsx72","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Chinese National \u2018863\u2019 Project","award":["2006AA020603, 2008AA02Z303"],"award-info":[{"award-number":["2006AA020603, 2008AA02Z303"]}]},{"name":"National \u2018New Drug Innovation\u2019","award":["2009ZX09401-003, 2008ZX09312, 2012ZX09303012"],"award-info":[{"award-number":["2009ZX09401-003, 2008ZX09312, 2012ZX09303012"]}]},{"name":"Guangdong Province","award":["2011A080501009, 2003A10903"],"award-info":[{"award-number":["2011A080501009, 2003A10903"]}]},{"name":"Shenzhen Municipal Government","award":["2010-1600"],"award-info":[{"award-number":["2010-1600"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1093\/annonc\/mdv237","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T20:45:12Z","timestamp":1435092312000},"page":"1766-1771","source":"Crossref","is-referenced-by-count":338,"title":["Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma"],"prefix":"10.1016","volume":"26","author":[{"given":"Y.","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1093\/annonc\/mdv237_bb0010","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","article-title":"Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification","volume":"138","author":"Sun","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"25","key":"10.1093\/annonc\/mdv237_bb0015","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdv237_bb0020","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdv237_bb0025","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv237_bb0030","unstructured":"U.S. Food and Drug Administration. Highlights of Prescribing Information for BELEODAQ\u00ae (belinostat). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206256lbl.pdf (30 October 2014, date last accessed)."},{"issue":"3","key":"10.1093\/annonc\/mdv237_bb0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1568011043352948","article-title":"Quantitative structure-activity relationship study of histone deacetylase iinhibitors","volume":"4","author":"Xie","year":"2004","journal-title":"Curr Med Chem Anticancer Agents"},{"issue":"4","key":"10.1093\/annonc\/mdv237_bb0040","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1093\/annonc\/mdv237_bb0045","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1042\/BJ20111685","article-title":"CS055 (Chidamide\/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells","volume":"443","author":"Gong","year":"2012","journal-title":"Biochem J"},{"issue":"8","key":"10.1093\/annonc\/mdv237_bb0050","doi-asserted-by":"crossref","first-page":"e70522","DOI":"10.1371\/journal.pone.0070522","article-title":"Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine","volume":"8","author":"Yao","year":"2013","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdv237_bb0055","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1039\/C4MD00350K","article-title":"Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment","volume":"5","author":"Pan","year":"2014","journal-title":"Med Chem Commun"},{"issue":"4","key":"10.1093\/annonc\/mdv237_bb0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.biopha.2014.03.011","article-title":"Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in non-small-cell lung cancer cells","volume":"68","author":"Zhou","year":"2014","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10.1093\/annonc\/mdv237_bb0065","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00280-012-1847-5","article-title":"Phase I study of chidamide (CS055\/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas","volume":"69","author":"Dong","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"suppl","key":"10.1093\/annonc\/mdv237_bb0070","article-title":"Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"31","author":"Shi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdv237_bb0075","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdv237_bb0080","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1093\/annonc\/mdv237_bb0085","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1093\/annonc\/mdv237_bb0090","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdv237_bb0095","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1093\/annonc\/mdv237_bb0100","unstructured":"China Food and Drug Administration. Approval summary for Epidaza\u00ae (Chidamide). www.cde.org.cn\/reviewDe.do?method=showFAQ&id=127 (9 February 2015, date last accessed)."}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/8\/1766\/5030492\/mdv237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:52:38Z","timestamp":1624506758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419318617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0923753419318617"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv237","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725585447.793539750","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}